PALUPA Medical Ltd. is a Startup built by three Scientists (Dr. Marios Pantzaris, Mr George Loukaides and Dr. Ioannis Patrikios), with the support of Helix Business Incubator, a high tech and innovation incubator.
The company was founded in 2006 and the initial goal was to design, plan, and execute a pioneer and innovative research program for the treatment of Multiple Sclerosis (MS) by investigating the safety and therapeutic effect of a nutritional-drug formulation (nutraceutical) for the disease. During the initial period, the company got involved in designing and executing all components of the Drug Development Process such as:
The company continued its activities as a research and innovation company and completed another 4 clinical studies, including a Phase III study (the MINERAL STUDY) both for Parkinson’s and Multiple Sclerosis.
Marios C. Pantzaris, George N. Loukaides, Evangelia E. Ntzani & Ioannis S. Patrikios. A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids 2with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial. BMJ Open 2013; 3:e002170.doi:10.1136/bmjopen-2012-00217
At PALUPA Medical Ltd., our mission is to improve the quality of life for people living with multiple sclerosis (MS) by providing a safe, effective and natural dietary supplement. We are committed to advancing scientific research and clinical trials to develop innovative treatments for chronic incurable diseases such as MS and to promote a holistic approach that integrates traditional and alternative therapies.
Our values of scientific rigor, patient-centered care, sustainability, transparency and innovation guide everything we do as we work to make a positive difference in the lives of multiple sclerosis patients around the world.
At PALUPA Medical Ltd., we are guided by a set of core values that reflect our commitment to scientific excellence and patient-centered care. We believe in the importance of rigorous scientific testing and development to ensure the safety and efficacy of our products and are dedicated to providing patient-centered care that meets the unique needs of people living with MS. We prioritize sustainability in our manufacturing and distribution practices and are committed to transparency and honesty in all of our interactions with customers and healthcare providers. Above all, we value innovation and strive to develop cutting-edge solutions to improve the lives of multiple sclerosis patients and push the boundaries of scientific research in the field of chronic diseases.
Professor of Medical Biochemistry, Lipidologist/ Immunologist Medical School, European University of Cyprus
Dr Ioannis Patrikios is a professor and Deputy Dean at the Medical School of the European University of Cyprus and a Scientific Collaborator at the Cyprus Institute of Neurology and Genetics
Senior Neurologist, Professor, The Cyprus School of Molecular Medicine
Dr Marios Pantzaris is a Head of Neurology Clinic C at the Cyprus Institute of Neurologist and Genetics
Registered Dietician and Clinical Nutritionist
Dr Marios Pantzaris is a Head of Neurology Clinic C at the Cyprus Institute of Neurologist and Genetics
Through collaborations with specialized partners, fully trained professionals, and distinguished scientists in the Health sector, Uppervis Pharmaceuticals aims to establish its presence as a leading pharmaceutical company.